Inside the β Cell: Molecular Stress Response Pathways in Diabetes Pathogenesis

Abhishek Kulkarni,1,∗ Charanya Muralidharan,1,∗ Sarah C. May,1 Sarah A. Tersey,1 and Raghavendra G. Mirmira1

1Kovler Diabetes Center and Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA

Correspondence: Raghavendra G. Mirmira, MD, PhD, Kovler Diabetes Center and Department of Medicine, The University of Chicago, 900 E 57th St, KCB 8132, Chicago, IL 60637, USA. Email: mirmira@uchicago.edu.

∗A.K. and C.M. contributed equally to this work.

Abstract

The pathogeneses of the 2 major forms of diabetes, type 1 and type 2, differ with respect to their major molecular insults (loss of immune tolerance and onset of tissue insulin resistance, respectively). However, evidence suggests that dysfunction and/or death of insulin-producing β-cells is common to virtually all forms of diabetes. Although the mechanisms underlying β-cell dysfunction remain incompletely characterized, recent years have witnessed major advances in our understanding of the molecular pathways that contribute to the demise of the β-cell. Cellular and environmental factors contribute to β-cell dysfunction/loss through the activation of molecular pathways that exacerbate endoplasmic reticulum stress, the integrated stress response, oxidative stress, and impaired autophagy. Whereas many of these stress responsive pathways are interconnected, their individual contributions to glucose homeostasis and β-cell health have been elucidated through the development and interrogation of animal models. In these studies, genetic models and pharmacological compounds have enabled the identification of genes and proteins specifically involved in β-cell dysfunction during diabetes pathogenesis. Here, we review the critical stress response pathways that are activated in β cells in the context of the animal models.

Key Words: islet, endoplasmic reticulum stress, autophagy, integrated stress response, diabetes

Abbreviations: 12-LOX, 12-lipoxygenase; ATF6, activating transcription factor 6; CHOP, C/EBP-homologous protein; DHPS, deoxyhypusine synthase; ER, endoplasmic reticulum; GCN2, general control nonderepressible 2; GPX, glutathione peroxidase; GST, glutathione-S-transferase; HRI, heme-regulated inhibitor; IRE1α, inositol requiring enzyme1α; ISR, integrated stress response; JNK, c-Jun N-terminal kinase; Keap1, Kelch-like ECH-associated protein 1; LC3, light chain 3; mRNA, messenger RNA; mTORC1, mammalian target of rapamycin complex 1; NF-kB, nuclear factor-kB; NOD, nonobese diabetic; NQ-01, NAD(P)H: quinone oxidoreductase 1; NRF2, nuclear factor-erythroid factor 2-related factor 2; PERK, PKR-like endoplasmic reticulum kinase; PKR, protein kinase R; ROS, reactive oxygen species; SOD, superoxide dismutase; STAT, signal transducer and activator of transcription; STZ, streptozotocin; T1D, type 1 diabetes; T2D, type 2 diabetes; tRNA, transfer RNA; TUDCA, tauroursodeoxycholic acid; TXNIP, thioredoxin interacting protein; UPR, unfolded protein response; XBP1, X-box-binding protein 1.

Diabetes is a syndromic disorder characterized by hyperglycemia that includes manifestations of dyslipidemia, neuropathy, and microvascular and macrovascular complications. Worldwide, diabetes has increased to epidemic proportions, afflicting hundreds of millions of individuals (1). The traditional classification of the disorder as either type 1 (T1D) (β-cell autoimmunity-mediated) or type 2 (T2D) (insulin resistance and β-cell dysfunction-mediated) belies a more heterogeneous pathophysiology that, in some individuals, exhibit features of more than one type. For example, a recent study showed that up to 41% of individuals with T2D exhibit evidence of autoimmunity (islet β-cell-specific T-cell reactivity) with higher frequency of β-cell dysfunction (2). Conversely, in individuals with T1D, postmortem studies show that less than 24% of T1D individuals have any detectable pathologic evidence of insulitis (3). Other studies show a striking persistence of proinsulin secretion even in longstanding T1D (4), reflecting preservation of β cells in a disorder thought to be defined by their complete absence (5).

These and other studies describe an overall picture wherein “endotypes” of T1D, T2D, and other, less common forms (eg, secondary diabetes, monogenic diabetes, gestational diabetes, ketosis-prone diabetes) represent disorders along a phenotypic and pathologic spectrum with an underlying feature being the loss or dysfunction of insulin-producing β cells. As a central focus of disease, β cells must maintain regulated insulin release despite the prevalence of “stressors” (proinflammatory cytokines, free fatty acids, elevated glucose) that are characteristic of the disease process. The nature of the β-cell response to these diabeticogenic stressors is arguably the single most crucial factor in the progression to disease since it dictates the robustness of insulin release as well as production of antigens that trigger the immune response. In this mini-review, we discuss key molecular pathways and processes triggered by diabeticogenic stressors—endoplasmic reticulum (ER) stress, the integrated stress response (ISR), the oxidative stress response, autophagy, and cellular senescence—and how these processes or their dysregulation contribute to β-cell dysfunction.
Endoplasmic Reticulum Stress in β-Cell Dysfunction

ER stress occurs when the demand for protein folding exceeds the ER folding capacity (6). As specialized secretory cells, β cells have a well-developed ER and several mechanisms in place to handle the enormous demand for insulin protein folding (7). Normally, β cells respond to alterations in blood glucose levels with a proportional synthesis and secretion of insulin. However, increased insulin demands during insulin resistance or the loss of β-cell mass from autoimmune attack creates an increased synthetic demand on residual β cells, thereby triggering ER stress. Studies both in mice and humans have explored the role of ER stress in diabetes (8, 9). ER stress may exacerbate or trigger T1D in mice, as evidenced by both the activation of ER stress-related genes and the expansion of ER in β cells (10, 11). Likewise, ER stress markers are elevated in β cells from pancreatic tissues of donors with T1D (12). Similar evidence has been presented in the context of T2D and has been well-reviewed previously (13). In the setting of ER stress, misfolded proteins are often the target of new post-translational modifications, which serve as neoantigens that activate the immune response in T1D (14).

Unfolded Protein Response Is a Homeostatic Mechanism to Mitigate Endoplasmic Reticulum Stress

To alleviate ER stress and regain ER homeostasis, cells activate the unfolded protein response (UPR) pathway that (a) slows global protein synthesis; (b) upregulates chaperones that aid in protein folding; and (c) activates ER-associated degradation to degrade irreparably misfolded proteins (15). This response is activated by 3 UPR stress sensors: inositol requiring enzyme 1α (IRE1α), activating transcription factor 6 (ATF6), and PKR-like endoplasmic reticulum kinase (PERK) (Fig. 1). Under normal conditions, the UPR sensors bind to a chaperone, binding immunoglobulin protein (BiP or GRP78) (16). Under ER stress conditions, BiP changes conformation and dissociates from the UPR sensors. BiP then binds to misfolded proteins and shuttles them from the ER lumen to the cytoplasm for proteasomal degradation (17). Deletion of any of the UPR sensors (IRE-1α, ATF6, or PERK) in mice induces diabetes, decreases β-cell mass, and impairs glucose metabolism (18–21).

Three “Arms” of the Unfolded Protein Response Are Essential for Endoplasmic Reticulum Homeostasis in β Cells

When activated by ER stress, IRE1α uses its endoribonuclease domain to splice Xbp1 messenger RNA (mRNA) to ensure encoding of mature X-box-binding protein 1 (XBP1) (22). XBP1 is a transcription factor that promotes expression of chaperones and ER-associated degradation proteins (eg, the Sel1L-Hrd1 complex) (23). β-cell–specific deletion of Sel1L, which is a cofactor of Hrd1, impairs ER-associated degradation and results in loss of β-cell identity (13). Conditional, β-cell–specific deletion of the gene encoding IRE1α (Ern1) in mice impairs glycemic control, decreases insulin secretion, and decreases folding of proinsulin (19). Similarly, β-cell–specific deletion of Xbp1 in mice decreases insulin secretion and results in hyperglycemia (24). The IRE1α pathway could help delay T1D development.

The second arm of the UPR, ATF6, has an autocataytic site that is cleaved by site 1/2 proteases (S1P and S2P) in the Golgi (25, 26). Cleaved ATF6 acts as a transcription factor to activate genes encoding chaperones and ER-associated degradation proteins (27). ATF6 protects against viral infection-induced T1D in mice on administration of tauroursodeoxycholic acid (TUDCA) to enhance protein folding. These effects were not seen in animals with β-cell–specific Atf6 deletion, suggesting that TUDCA exerts its effects through the ATF6 arm of the UPR pathway (10). However, more studies need to be conducted to assess the role of ATF6 in T1D.

The third arm of the UPR, PERK, phosphorylates eukaryotic translation initiation factor 2 subunit 1 (eIF2α also known as eIF2a), which inhibits global mRNA translation (28). As expected, PERK-deficient mice show decreased eIF2α phosphorylation, enhanced global mRNA translation, and increased ER stress, which is accompanied by loss of β cells (21, 29). Germline deletion of the gene encoding PERK (Eif2ak3) results in neonatal diabetes (30), and its postnatal deletion results in a pleiotropic response in β cells with increased proliferation, and accumulation of proinsulin preceding increased cell death (31). With chronic ER stress, PERK promotes translation of the gene encoding activating transcription factor 4 (ATF4), which activates the gene encoding C/EBP-homologous protein (CHOP) to promote apoptosis (32). Thus, deletion of CHOP in C57BL/6 mice expands β-cell mass, alleviates ER stress, and improves glycemic control (33, 34). Although whole-body deletion of CHOP in non-obese diabetic (NOD) mice (a mouse model of T1D) has no effect on diabetes incidence, apoptosis, or insulinitis, it reduces the early production of insulin autoantibodies (35). Studies suggest that the UPR and PERK pathway also play a role in human T1D. These studies report a strikingly similar trend of increased CHOP and BiP expression in islets isolated both from mice and human donors with T1D (11, 12). In addition, islets from donors with T1D have decreased expression of genes involved in the adaptation to ER stress (36). Collectively, these studies demonstrate that β-cell ER stress is activated during the pathogenesis of T1D and may contribute to β-cell dysfunction.

It should be noted that other proteins can affect the ER stress response indirectly, either by altering ER calcium homeostasis or altering transcription of genes that are required for ER homeostasis. For example, sarcoendoplasmic reticulum Ca2+ ATPase 2 (SERCA2) maintains a 3-fold higher concentration of Ca2+ within the ER, relative to the cytosol, to ensure proper functioning of ER-resident chaperones and protein folding machinery (37). Mice haploinsufficient for the gene encoding SERCA2 show elevated ER stress as well as impaired glucose tolerance in β cells after high-fat diet feeding (38). Similarly, deletion or deficiency of the gene encoding Wolframin (Wfs1), another protein required for ER calcium loading, results in ER stress, impaired glucose tolerance, and β-cell death (39). In humans, mutations in the WFS1 gene result in Wolfram syndrome, which includes β-cell loss (with juvenile-onset diabetes), sensorineural hearing loss, and optic atrophy (40). Thus, both direct and indirect causes of ER stress can lead to T1D. Collectively, the literature on β-cell ER stress supports the notion that the UPR and ER stress
function as homeostatic mechanisms that allow the cell to recover from stresses that enhance protein demands, but that this adaptive mechanism can become maladaptive in the setting of prolonged stress and lead to eventual impairment and death of β cells.

Integrated Stress Response
The PERK pathway of the UPR is also a branch of the ISR. The ISR is a cytoprotective response to stresses such as viral infections, inflammation, and changes in gut microbiota and nutrient availability. These stresses are sensed by at least 1 of 4 specialized protein kinases: PERK, general control nondepressible 2 (GCN2), protein kinase R (PKR), or heme-regulated inhibitor (HRI) (41). Each activated kinase phosphorylates eIF2α, which represses global translation and simultaneously promotes translation of mRNAs that mitigate stress (28) (see Fig. 1). The ISR, like the UPR, is an adaptive response whose activation is designed to relieve cellular stress and promote survival. However, when ISR activation is chronic and stress persists, the ISR can promote cellular apoptosis (42). In pancreatic β cells, this chronic activation of the ISR is now being investigated, as it may contribute to diabetes pathogenesis. Each of the 4 eIF2α kinases is activated on its dimerization and autophosphorylation. Although their catalytic domains share homology, their regulatory domains differ substantially so that each kinase can respond to distinct stress signals (43, 44). As noted previously, PERK is activated by ER stress. We next discuss the remaining 3 eIF2α kinases in greater depth. We also review the existing studies on β-cell function and diabetes pathogenesis that display hallmarks of ISR activation.

eIF2α Kinases of the Integrated Stress Response
The ISR kinase GCN2 senses cellular amino acid levels (21). During amino acid starvation, there is an increase in the levels of uncharged transfer RNAs (tRNAs) (45). These uncharged tRNAs bind to the histidyl-tRNA synthetase-related domain of GCN2, which activates the GCN2 kinase domain through autophosphorylation. Once activated, GCN2 phosphorylates eIF2α (46). Global deletion of the gene encoding GCN2 (Eif2ak4) in mice results in no overt phenotype. However, on high-fat diet feeding, Eif2ak4−/− mice exhibit impaired glucose tolerance and reduced β-cell mass (47). A role for GCN2 in the context of T1D pathogenesis has not yet been reported.

PKR is activated predominantly by double-stranded RNA in response to viral infection (48, 49). When its C-terminal kinase domains dimerize, PKR becomes autophosphorylated at T446 and subsequently activated (50). Activated PKR phosphorylates eIF2α to inhibit viral and host protein synthesis. In addition to double-stranded RNA, PKR can be activated by oxidative and ER stress, growth factor deprivation, cytokines, bacterial infection, ribotoxic stress, stress granules, and heparin (as reviewed in Pakos-Zebrucka et al) (41). Viral infections, which activate PKR, have been implicated as early triggers of T1D, and islets from T1D donors show higher expression of PKR (51). PKR has also recently been
demonstrated to be activated in human islets following infection by the SARS-CoV-2 virus, and its subsequent signaling cascade may lead to β-cell dysfunction in the setting of COVID-19 (52). In a mouse study, inhibiting PKR protected against streptozotocin (STZ)-induced diabetes by downregulating the c-Jun N-terminal kinase (JNK) pathway (53). Hence, PKR may play a role in T1D development after viral infections as well as intracellular stresses.

HRI kinase is also activated on dimerization and autophosphorylation of its kinase domain. Its kinase activity is regulated by 2 heme-binding domains at the N-terminus and the kinase insertion domain. Heme inhibits HRI kinase activity by promoting disulfide bonds that lock HRI in an inactive dimer (54). Conversely, when heme is absent, noncovalent interactions form between HRI molecules, resulting in an active HRI dimer. Besides heme absence, other known activators of HRI include oxidative stress, nitric oxide, and 26S proteasome inhibition (55–57). The mechanisms of HRI activation by these stressors are unknown. To date, most studies of HRI have been performed in erythroid cells owing to the higher expression of HRI in erythrocytes. However, heme-independent HRI activators, such as oxidative stress and nitric oxide (synthesized in inflammation), are active in β cells during the initiation and progression of diabetes. Currently, no studies link prolonged activation of HRI to β-cell dysfunction.

As mentioned, all 4 kinases phosphorylate eIF2α (41). EIF2α is the critical regulatory subunit of the eIF2 complex (also consisting of eIF2β and eIF2γ), which plays a central role in initiating mRNA translation. When eIF2α is phosphorylated, it blocks eIF2β-mediated exchange of GDP for GTP, which is needed to deliver initiator methionyl-tRNA to the preinitiation complex. As a result, phosphorylated eIF2α globally reduces mRNA translation. However, a select set of mRNAs become preferentially translated that relieve cell stress and reinitiate translation (58).

Another outcome of ISR activation is the formation of non-membranous stress granules that consist of translationally repressed mRNA and associated RNA-binding proteins (59). Because stress granules can also be released as extracellular vesicle contents (60–62), their contents could serve as a means of β-cell-to-immune cell communication in T1D (63). Under normal conditions, stress granule formation is reversible. However, under chronic stress or pathological conditions, stress granules accumulate, either due to increased stress granule formation or decreased stress granule clearance (64). In human islets, inhibiting the ISR reduced stress granule formation after inflammatory cytokine treatment and increased production of the immunosuppressive protein PD-L1 (65). A key player in stress granule assembly is Ras GTPase-activating protein-binding protein 1 (G3BP1); deleting G3BP1 in neurons resulted in fewer stress granules (66). Another player in stress granule assembly is deoxyhypusine synthase (DHPS), an enzyme required for the posttranslational modification (hypusination) of eukaryotic translation initiation factor 5A (eIF5A). Knockdown of DHPS results in significant inhibition of oxidative-stress induced stress granule formation (67–69), and systemic DHPS inhibition in NOD mice reduces ER stress and incidence of autoimmune diabetes (70, 71). Interestingly, another study suggests that the hypusine circuit can also promote ER stress and the IRE-1α pathway of the UPR (72). Together, these studies suggest that inhibition of stress granule assembly, perhaps through the manipulation of the ISR, could play a role in potentially delaying autoimmune diabetes incidence.

Additional studies suggest that a prolonged ISR contributes to T1D pathogenesis. Recent evidence points toward dysregulation of the ISR in pancreata of pre-T1D autoantibody-positive (AAb+) donors owing to repression of ISR kinase gene expression (PERK, GCN2, PKR) (73). However, there was elevated expression of the ISR genes in T1D donor pancreata, suggesting a chronic activation of ISR. Notably, there is an increase in EIF2AK3 (PERK) in T1D donor pancreata, consistent with activation of the ER stress arm of the ISR (73). As such, these data suggest that attenuating the ISR pathway may protect against diabetes. Indeed, during SARS-CoV2 infection of β cells, which can suppress insulin secretion and worsen diabetes, inhibiting the ISR allowed for recovery of β-cell function and reversed markers of cellular dedifferentiation (52). Further studies are needed to clarify the timing, magnitude, and duration of the ISR during diabetes pathogenesis as new ISR-targeting therapies are investigated. Collectively, emerging data on the ISR indicate that phosphorylation of eIF2α may be a mechanism to attenuate mRNA translation that is not restricted simply to the PERK arm of the ER stress cascade, and that other factors not directly related to ER stress (eg, viral infection or nutrient deprivation) may be contributing factors in the eventual decline of β cells in diabetes.

**Oxidative Stress in β-Cell Dysfunction**

Oxidative stress and ER stress pathways are closely intertwined, as oxidative stress can lead to protein misfolding and ER stress, and ER stress can affect redox homeostasis (see Cao and Kaufman for a review) (74). Oxidative stress occurs when the accumulation of reactive oxygen species (ROS) exceeds the antioxidant scavenging capacity of the cell. Failure to resolve ROS accumulation leads to oxidative stress, damage to cellular components, and ultimately cell death (75). These highly reactive radicals are produced by mechanisms that are both endogenous and exogenous with respect to the β cells (Fig. 2) (76). Endogenous ROS is released as a byproduct of metabolic activity in mitochondria (77) and peroxisomes (78, 79). Other endogenous producers of free radicals include NADPH oxidases, nitric oxide synthases, and lipoygenases (76, 80, 81). The exogenous factors that induce ROS generation in β cells include cytokines, glucose, and free fatty acids, as well as environmental factors such as radiation, chemicals, carcinogens, cigarette smoke, and alcohol consumption (76, 82). Hyperglycemia increases intracellular levels of advanced glycation end products, glucose oxidation, and lipid peroxidation (83), leading to ROS generation (84) and ultimately diminishing insulin release. Studies have also shown that hyperinsulinemia promotes the generation of free radicals by an NADPH-dependent mechanism (85). In addition, islets may have lower levels of antioxidant enzymes than other tissues, making them more vulnerable to oxidative damage (86, 87). Because β cells have an exceptionally high protein biosynthetic load, excessive NADPH is generated leading to elevated superoxide anion radical (O2·−) production by promoting NADPH oxidase activity, rendering β cells susceptible to oxidative damage (88).

Oxidative stress damages various cellular targets, including nucleic acids, lipids, and proteins (89). DNA oxidation results in single-stranded breaks and formation of 8-hydroxyguanosine, a relatively stable oxidation product used to measure oxidative DNA damage (90). DNA damage is associated with
cellular senescence, apoptosis, and cancer (91). Lipid oxidation via lipoxigenases and cyclooxygenases can disrupt membrane integrity and fluidity and increase cell permeability. Moreover, lipid oxidation generates more radicals that can then damage DNA and proteins (92–94). Protein oxidation can lead to alteration of enzyme activity, loss of protein function, protein aggregation, and increased immunogenicity (95–97). Thus, ROS can inflict widespread damage to cells.

At low levels, ROS can act as important second messengers (98). However, when there is an accumulation of ROS, these signaling pathways may promote diabetes pathogenesis. For example, ROS activate mammalian target of rapamycin complex 1 (mTORC1), a protein complex downstream of AKT signaling that is growth-promoting but at chronic levels of activation can also promote apoptosis (99). ROS can also activate mitogen-activated protein kinase, extracellularly regulated kinase, and JNK pathways, which promote cellular senescence and trigger apoptosis in β cells (100). Importantly, ROS can induce inflammation through nuclear factor-κB (NF-κB), thereby promoting the production of proinflammatory cytokines tumor necrosis factor-α and interleukin-6 (101, 102). Catalase is a peroxisomal enzyme that reduces hydrogen peroxide and helps remove islet amyloid fibrils, which are formed from misfolded islet amyloid polypeptide and impair β-cell function (109). Cat−/− mice have impaired glucose tolerance (110). SODs are superoxide scavengers located on the mitochondrial and extracellular matrix (111). Deficiency of extracellular SOD exacerbates β-cell damage on alloxan-induced diabetes (112). Similarly, deficiency of Cu, Zn superoxide dismutase (SOD1) in mice increases blood glucose, impairs glucose-stimulated insulin secretion, and downregulates PDX1 signaling (113). GPXs are located in the cytoplasm and mitochondria and reduce hydrogen peroxide and peroxide radicals (114). GPX1-deficient mice have a similar but less pronounced phenotype as SOD1-deficient mice (113). However, mouse deficiency of both SOD1 and GPX1 does not exacerbate either individual phenotype, suggesting that superoxide-mediated oxidative stress is primarily responsible for diabetes outcomes (113). NQ-O1 detoxifies quinones and induces an antioxidant response (103). Notably, the plasma of individuals with early T1D exhibits an increase in oxidative stress but no increase in antioxidant activity, implying a failed antioxidant response system (106). In support of this finding, induction of NRF2 in the NOD murine model of autoimmune diabetes represses the onset of hyperglycemia (107). In further support, hypomorphs or deletions of Keap1 in NOD mice activate NRF2, reduce T-cell infiltrates into the islet, and protect against hyperglycemia (107). Collectively, these studies confirm the importance of the antioxidant system in maintaining β-cell health.

Figure 2. Oxidative stress promotes an antioxidant response. Exposure to different stressors generates reactive oxygen species (ROS) through the NADPH oxidase system, mitochondria, peroxisomes, and through endogenous enzymatic reactions. Abnormal accumulation of ROS triggers the dissociation of the master antioxidant response transcription factor NRF2 from its inhibitor KEAP1. Free NRF2 translocates to the nucleus, binds to antioxidant response elements (ARE), and promotes expression of anti-oxidant response genes.
Deficiency of NQ-O1 worsens STZ-induced β-cell death and accelerates hyperglycemia (116). Last, GSTs inactivate secondary metabolic byproducts, such as unsaturated aldehydes, epoxides, and hydroperoxides (117). In mice, deficiency of GSTP (p1 isoform) does not affect fasting blood insulin or glucose levels but impairs glucose tolerance, which was reversed by inhibiting JNK (118). This suggests that the glucose intolerance with GSTP deletion is mediated through activation of the JNK pathway.

In addition to the major antioxidant enzymes, other proteins regulate oxidative stress through NRF2 signaling, including thioredoxin (119), thioredoxin interacting protein (TXNIP) (120, 121), thioredoxin reductase 1, and 12-lipoxygenase (12-LOX) (122–126). Inhibition of 12-LOX or thioredoxin reductase 1 in islets results in upregulation of the antioxidant response through NRF2 (124, 127). Also, 12-LOX plays a role both in myeloid cells (macrophages) and β cells, as tissue-specific removal of 12-LOX in either cell type in NOD mice (63, 128) protects against autoimmune diabetes. Loss of 12-LOX in β cells in a model of T2D protects against obesity-induced dysglycemia (126). Similarly, overexpression of thioredoxin in β cells of NOD mice delays the development of autoimmune diabetes (119). By contrast, loss of TXNIP (an inhibitor of thioredoxin) in mice leads to increased β-cell mass and resistance to STZ-induced diabetes development (129).

Finally, it was demonstrated that TXNIP induces the production of islet amyloid polypeptide in β cells, suggesting that activity of TXNIP may promote production of islet amyloid polypeptide-induced β-cell dysfunction in T2D (130). Together, these studies suggest that identification of targets in the antioxidant response pathway would yield more therapeutically possible both for T1D and T2D.

Mouse and human studies suggest that oxidative stress plays a role in T1D pathogenesis. In prediabetic NOD mice, oxidative stress–induced damage is elevated in islets and vascular tissues (131). This oxidative stress in β cells is amplified by the aberrant cytokine production of infiltrating immune cells (132). In humans with T1D, markers of oxidative stress such as lipid peroxides are elevated, whereas levels of antioxidants like SOD and GPX are reduced (133). Recently, a study found that serum levels of derivatives of reactive oxygen metabolites were significantly increased in youth with T1D, consistent with an increase in systemic oxidative stress in T1D (134). Longitudinal profiling of plasma proteins during T1D progression consistently shows increased expression of oxidative stress markers and a spike in antioxidant enzymes that immediately precedes conversion to islet autoimmunity (135). In concordance, another study found that SOD antioxidant activity is elevated in the erythrocytes of children at the onset of T1D, followed by a decline in antioxidant defense over time (136). Predictably, individuals with hereditary catalase deficiency (known as acatalasemia) have higher prevalence of diabetes (137).

Taken together, the aforementioned studies implicate a critical role for oxidative species in altering protein structure and function in the β cell. Given their relatively low native antioxidant response, β cells function in a precarious environment where prolonged alterations in oxidative species or redox states can have a profound effect on function and survival.

**Autophagy in Diabetes**

Autophagy is an evolutionarily conserved degradation and recycling process that is triggered by viral infections, ER stress, oxidative stress, viral infections, or nutrient starvation (138). Different forms of autophagy are activated under different contexts. In macroautophagy, a host of autophagy-related genes (Atg) (139) work through a series of well-orchestrated steps to sequester substrates in double-membranated vesicles called phagophores. Eventually, the microtubule-associated protein 1 light chain 3 (LC3) conjugation system (made up of LC3, ATG7, and ATG3) causes LC3 to become lipidated, which helps expand phagophores into autophagosomes. The autophagosome cargo is obtained directly from the cytoplasm or brought to the phagophore by adapter proteins such as p62 (selective autophagy). Autophagosomes then fuse with the lysosomes, and enzymes in the acidic lysosomal lumen degrade and recycle cargo into building blocks that the cell can use to regain homeostasis (140). In chaperone-mediated autophagy, proteins containing a “KFERQ” motif are targeted for degradation and chaperoned to the lysosomes where they are ultimately degraded (141). In microautophagy, proteins and organelles directly invaginate the lysosomes for degradation and recycling (142). A schematic of the autophagy process and the different types of autophagy is presented in Fig. 3.

Many genes involved in selective autophagy contain T1D susceptibility loci (143). Thus, there has been a lot of interest in understanding the role of autophagy in T1D. Dysfunctional autophagy is detrimental to β-cell health and reduces insulin secretion (144, 145). Additionally, inhibiting autophagy results in chronic ER stress and β-cell apoptosis (146). Organelle-specific autophagy—such as mitophagy (degrades mitochondria), crinophagy (degrades insulin granules), and lipophagy (degrades lipid droplets)—also regulates β-cell function (145). The roles of different types of autophagy in β cells have been reviewed in depth (147). Here, we focus on models that have been used to study β-cell autophagy in diabetes, as well as other autophagy models that could be applied to β cells.

**Molecular Mechanisms of Autophagy and Their Role in β-Cell Health and Disease**

The first step in autophagosome membrane formation involves a complex of proteins, one of which is Beclin 1. Constitutively active mutant Beclin 1 mice (and therefore constitutively active autophagy) have improved insulin sensitivity but impaired insulin secretion resulting in glucose intolerance on a high-fat diet (148). In selective autophagy, the adapter proteins have LC3 interacting regions, which help tether substrates to LC3 on the autophagosome membrane. One of these adapter proteins is p62. LC3 and p62, as autophagosome markers, are used to detect impaired autophagy when they accumulate. LC3 has been shown to accumulate in insulin-positive cells in autoantibody-positive donors (149) and both LC3 and p62 in T2D human islets (150, 151). However, deletion of the gene encoding p62 in β cells displays no overt phenotype, suggesting that p62 is dispensable during normal β-cell function (152). Global and β-cell–specific deletions of Parkin, a protein involved in mitochondrial degradation, show contrasting effects. Whereas global deletion impairs glucose tolerance (153), β-cell–specific deletion has no apparent effect on glucose tolerance and insulin secretion (154). These studies highlight the importance of focusing on β-cell–specific deletions to elucidate the functional roles for autophagy-related genes in β-cell health. Genetic models of autophagy in the context of diabetes have been...
previously reviewed (145). Briefly, pancreas-specific deletion of Clec16a—encoding an E3 ubiquitin ligase and T1D risk gene that functions in mitophagy (155)—impairs glucose tolerance, glucose-stimulated insulin secretion, and mitochondrial respiration. Similarly, β-cell–specific deletion of Miro1, a mitophagy-related gene whose encoded protein prevents translocation of Parkin to mitochondria, impairs insulin secretion, and disrupts mitochondrial function (156).

All types of autophagy end with lysosomal degradation. Lysosomes must maintain a low pH to activate proteolytic cathepsin enzymes. The lysosomal lumen is acidified by a large multimeric vacuolar H+ ATPase complex consisting of 2 functional domains (v1 and v0), each containing about 6 to 8 subunits. In mice, β-cell–specific deletion of one of the subunits, Atp6ap2, leads to impaired insulin secretion and accumulation of vacuolar structures (157). Global deletion of the T1D-risk gene Ctsb, a lysosomal cysteine protease, disrupts insulin secretion and raises fasting blood glucose, further emphasizing the role of autophagy in maintaining β-cell homeostasis (158).

Although early autophagy has been studied in diabetes, there is little information on the role of lysosomes. Notably, both in T1D and T2D, there is possible dysfunction at the final clearance step by the lysosomes. Therefore, studies on lysosome biogenesis (eg, the role of lysosome transcription factor EB), acidification, and function (eg, the role of different cathepsins) will inform us on how to target this process in β cells to prevent diabetes progression. Additionally, the idea that microautophagy and chaperone-mediated autophagy maintain β-cell homeostasis has been understudied. Therefore, studies targeting each type of autophagy will reveal new targets that promote β-cell survival under stress conditions, both in T1D and T2D.

**Senescence in Diabetes**

When cellular stress is unmitigated, it leads to irreparable cell damage (eg, DNA damage) that forces cells to stop dividing and undergo senescence. Senescence causes cell cycle arrest, apoptosis resistance, and secretion of various senescence-associated factors that are collectively termed as senescence-associated secretory phenotype (159). The initial cell cycle exit is mediated by cyclin-dependent kinase inhibitors in the p53/p21CIP1 and/or p16INKa/Rb pathways. This is followed by an increase in senescence-associated β-galactosidase (SA-βgal) activity and release of senescence-associated secretory phenotypes that potentiate tissue remodeling by recruiting immune cells (160). In β cells, senescence-associated cyclin-dependent kinase inhibitors, such as p21 and p16, are activated under stress conditions (161, 162). Mice with a transgene that facilitates the targeted deletion of cells containing p16INKa (INK-ATTAC mice) have improved β-cell function (162), suggesting that modulation of the markers of cell cycle improves β-cell function.

Recent evidence shows that some remnant β cells in NOD mice and β cells in recent onset and long-standing T1D donors
have DNA damage-associated senescence features (163, 164).
These studies suggest that DNA damage–associated senescence is an early feature in the pathogenesis of T1D. Senescent β-cells of NOD mice exhibit increased expression of p21, p16^{INKA}, and the cell death regulator Bcl-2 and increased SA-β-gal activity (163). Notably, treatment of NOD mice with Bcl-2 inhibitors (senolytics) eliminates senescent cells and halts autoimmune destruction of β cells (163). Senolytics such as ABT263, which targets the Bcl-2 pathway, also restore β-cell identity and glucose mechanism in the context of T2D (162). To date, many studies have used p16^{INKA} genetic mouse lines to model senescence in β cells during T2D (162). Because p21 is also elevated in senescent cells, p21 genetic models (165) could help uncover new therapeutic targets. Whether senescence is a driver or aftermath of ER stress or oxidative stress is still debatable. However, recent evidence points toward the UPR being a major contributor that controls senescence hallmarks (166), suggesting that ER stress and oxidative stress might precede a senescence phenotype.

### Alternative Models to Study Endoplasmic Reticulum Stress, Oxidative Stress, Autophagy, and Senescence in Diabetes

Although mutant mouse models are ideal to study specific genes in diabetes pathogenesis, they are often time-consuming and laborious to develop. Additionally, because many stress response genes are essential housekeeping genes, many are embryonically lethal when deleted. Nevertheless, this issue can be circumvented by using conditional deletion of genes post maturity. This strategy can be especially challenging with difficult-to-breed mice, such as NOD mice. Gene delivery or knockdown techniques that use antisense oligos (167, 168), morpholinos (169, 170), and adeno-associated virus vectors (171) allow for targeted gene deletion or insertion without elaborate breeding schemes. These targeted gene delivery systems can also be combined with genetic models to further validate the role of the gene of interest.

Pharmacological inhibitors and activators provide additional insight into the role of pathways under different stress conditions. For example, the UPR and ER stress in β-cells and islets have been studied by exposing cells to various chemicals (172), such as thapsigargin (SERCA inhibitor), tunicamycin (inhibits glycosylation of nascent proteins), TUDCA (chemical chaperone), and imatinib (tyrosine kinase inhibitor). Similarly, oxidative stress in β cells has been studied with diabetogenic agents, such as STZ (173) and alloxan (88). Verapamil, a calcium channel blocker that lowers the antioxidant TXNIP levels, preserves β-cell function by modulating both oxidative stress and ER stress pathways (174).

To study autophagy, chemical manipulators that target different steps of the degradation pathway have been used successfully. For example, metformin targets adenosine

---

### Table 1. Mouse models for studying stress-related and stress-response pathways in β cells in the context of diabetes pathogenesis

| Pathway | Gene | Models | Key findings | References |
|---------|------|--------|--------------|------------|
| ER stress | Grp78 | Whole body Heterozygotes; overproduction in β cells | Improved glycemic levels; resistant to high-fat diet–induced hyperinsulinemia | (209, 210) |
|         | Eif2ak3 | Germline deletion | Impaired glycemic control, decreased proinsulin folding, decreased insulin secretion | (19) |
|         | Atf6 | β-cell–specific deletion | Increased β-cell apoptosis | (10) |
|         | Ern1 | β-cell–specific deletion | Improved glycemic control, increased insulin secretion | (24) |
|         | Xbp1 | β-cell–specific deletion | Reduced insulin secretion and hyperglycemia | (33–35) |
|         | Ddit3 | Whole-body deletion; β-cell–specific deletion | Improved glycemic control; increased β-cell mass; reduced ER stress; reduced production of insulin autoantibodies | (211) |
| ISR | Eif2ak4 | Whole-body deletion | Impaired glucose tolerance; reduced β-cell mass following high-fat diet feeding | (47) |
|         | Eif2s1 | Whole-body heterozygous and homozygous mutation (S51A) | Severe hypoglycemia; early lethality | (212, 213) |
| Oxidative stress | Nfe2l2 | Whole-body deletion | Impaired glucose tolerance; hyperglycemia | (104, 105) |
|         | Keap1 | Whole-body deletion | Delay in T1D incidence; reduction in T-cell infiltrates into islet | (107) |
|         | Sod | Whole-body deletion | Increased β-cell damage on alloxan exposure; hyperglycemia and impaired glucose-stimulated insulin secretion | (112, 113) |
|         | Gpx1 | Whole-body deletion | Reduced insulin secretion | (113) |
|         | Nqo1 | Whole-body deletion | Increased β-cell death and hyperglycemia | (116) |
|         | Gstp1 | Whole-body deletion | Impaired glucose tolerance | (118) |
| Autophagy | Atg7 | β-cell–specific deletion (embryonic); induced β-cell–specific deletion (adult) | Reduced β-cell mass; reduced insulin levels; impaired glucose tolerance; improved β-cell function on short-term deletion and impaired β-cell function on long-term deletion during high-fat diet | (144, 146, 214–217) |
|         | Rptor | β-cell–specific deletion (adult) | Reduced β-cell mass; hyperglycemia | (218) |
|         | Becn1 | Mutant (F121A) | Improved insulin sensitivity with impaired insulin secretion | (148) |
|         | Ss1tm1 | Whole-body deletion; β-cell–specific deletion | Insulin resistance and obesity (whole-body deletion); no apparent phenotype (β-cell–specific deletion) | (152, 219) |
|         | Prkn | Whole-body deletion; β-cell–specific deletion | Impaired glucose tolerance (whole-body deletion); normal glucose tolerance (β-cell–specific deletion) | (153, 154) |
|         | Clec16a | Pancreas-specific deletion | Impaired glucose tolerance; impaired glucose-stimulated insulin secretion | (155) |
|         | Miro1 | β-cell–specific deletion | Impaired insulin secretion and disrupted mitochondrial function | (156) |
|         | Atg6ap2 | β-cell–specific deletion | Impaired insulin secretion | (157) |
|         | Gsh | β-cell–specific deletion | Impaired insulin secretion; hyperglycemia | (158) |

**Abbreviations:** ER, endoplasmic reticulum; T1D, type 1 diabetes.
5′-monophosphate-activated protein kinase (AMPK), which inhibits mTORC1 and therefore promotes autophagy. Rapamycin, torin1, and resveratrol also inhibit mTORC1 to promote autophagy (175–177). BH3 mimetics induce autophagy by disrupting the interaction between Beclin 1 (a part of the PI3K complex) and Bcl-2. On the other hand, PI3K inhibitors, such as wortmannin, 3-methyladenine, and spautin-1, inhibit autophagy initiation. Similarly, ULK and ATG4B inhibitors prevent elongation of the phagophore (175–177). Autophagy can also be inhibited by blocking adapter proteins, such as p62 and optineurin, using LC3 interacting region inhibitors. The last stage of degradation, where autophagosomes fuse to lysosomes and components are degraded in the acidic lysosomal lumen, can be blocked by chloroquine, bafilomycin A, or cystatin B (175–177).

It is difficult to replicate senescence in vitro. However, a recent study using sublethal doses of etoposide showed a DNA damage–induced senescence phenotype in β cells, thereby paving the way for more relevant studies in vitro using human islets (178). Although these pharmacological strategies do not exactly mimic physiological stress responses, they can improve our understanding of the pathways involved in β-cell homeostasis (179).

In addition to chemical modulators, zebrafish represent tractable models for monitoring stress response systems in vivo, considering the ease of handling and optical transparency. For example, ER stress (180–185), oxidative stress (186–188), inflammation (189, 190), and autophagy (191) have been extensively studied using zebrafish models.

Stress Response Pathways Converge on Activation of Inflammation

The aforementioned stress pathways are capable of damaging β cells themselves; however, studies show that they primarily mediate their effects by activating local inflammation that amplifies the damage to the cells (192–194). Inflammation is a critical immune response that clears pathogens and damaged cells, repairs tissue, and releases molecular mediators that amplify or resolve inflammation (195). The inflammatory response involves a variety of cytokines, chemokines, and proteins that directly or indirectly induce IκB kinase-β (IκKB), JNK, or signal transducer and activator of transcription (STAT) signaling cascades. IκKB is involved in the activation of NF-kB–mediated inflammation, wherein NF-kB upregulates proinflammatory cytokines expression (196). Similarly, JNK signaling upregulates proinflammatory and profibrotic factors (197). Activation of different STATs by cytokines also promotes inflammation (198). When inflammation is limited and appropriate, it prevents disease. However, maladaptive inflammation often triggers the development and progression of diseases, including diabetes (199). T1D is an autoimmune disorder in which the islets are inflamed by substantial numbers of infiltrating immune cells, a condition known as insulinitis (200). Accumulating evidence suggests that the immune system is not only critical in T1D, but also has a substantial role in T2D pathogenesis. T2D is characterized by insulin insufficienty and insulin resistance. Among the factors contributing to T2D are oxidative stress, ER stress, glucotoxicity, lipotoxicity, and amyloid deposition in the pancreas. Interestingly, each of these factors is associated with inflammation (201–204). As a result, T2D is increasingly being viewed as an inflammatory condition, and immune system dysfunction is a focus of research in T2D pathogenesis. Because inflammation is common to both forms of diabetes, therapies that seek to dampen the stress response pathways could be critical for halting diabetes pathogenesis.

Conclusions

The UPR, antioxidant response, and autophagy are all activated by stress. Each of these stress response systems intersects with one another to promote cell survival and to maintain cellular homeostasis. However, prolonged activation redirects the cellular machinery into apoptosis and senescence (205), which both contribute to diabetes pathogenesis. In T1D and T2D, there is evidence of increased ER stress (11, 206), oxidative stress (131, 207), and autophagy (149, 151, 208). Although β cells can overcome acute ER stress, when overburdened, they fail to put the brakes on their stress mitigation systems and redirect themselves to destruction (36). Genetic mouse models have been key in identifying how these stress pathways contribute to β-cell dysfunction and death. We list these models in Table 1. Although global gene deletions provide valuable information, they do not specifically elucidate the role of the genes in β-cell health and function. Therefore, β-cell–specific genetic models and targeted chemical manipulations are critical for identifying potential therapeutic targets for T1D and T2D. Altogether, these studies highlight the need to harness strategies that reduce stress and restore β-cell homeostasis.

Acknowledgments

The following search terms were used either alone or in combination on PubMed to identify references for this review: islet stress, β-cell stress, oxidative stress, integrated stress response, autophagy, diabetes, type 1 diabetes, type 2 diabetes, neurotrophin, obesity, autoimmunity, insulin resistance, senescence, de-differentiation, virus, cytokines, lipotoxicity, hyperglycemia, glucolipotoxicity, free fatty acids, insulin, ER stress, and unfolded protein response.

Financial Support

Research in the Mirmira laboratory is supported by the National Institutes of Health (grant Nos. U01 DK127786, R01 DK124906, R01 DK060581, and R01 DK105588, all to R.G.M.; and P30 DK020595 to the University of Chicago), and Diabetes Research Connection awards (to C.M. and A.K.).

Author Contributions

Conception alization, A.K., C.M. and R.G.M.; writing—original draft preparation, C.M. and A.K.; writing—review and editing, C.M., A.K., S.C.M., S.A.T, and R.G.M.; supervision, R.G.M. All authors have read and agreed to the final version of the manuscript.

Disclosures

The authors have nothing to disclose.

Data Availability

Data sharing is not applicable to this article as no data sets were generated or analyzed during the present study.
References

1. Saiedi P, Petersohn I, Salpea P, et al; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.

2. Brooks-Worrell B, Hampe CS, Hattery EG, et al; GRADE Beta-cell Ancillary Study Network. Islet autoimmunity is highly prevalent and associated with diminished β-cell function in patients with type 2 diabetes in the GRADE study. Diabetes. 2022;71(6):1261-1271.

3. In’t Veld P. Insulitis in human type 1 diabetes: a comparison between patients and animal models. Semin Immunopathol. 2014;36(5):569-579.

4. Sins EK, Bahnsen HT, Nyalwidhe J, et al. Proinsulin secretion is a persistent feature of type 1 diabetes. Diabetes Care. 2019;42(2):258-264.

5. Campbell-Thompson M, Fu A, Kaddis JS, et al. Insulitis and β-cell mass in the natural history of type 1 diabetes. Diabetes. 2016;65(3):719-731.

6. Schröder M, Kaufman RJ. ER stress and the unfolded protein response. Mutat Res. 2005;569(1-2):29-63.

7. Papa FR. Endoplasmic reticulum stress, pancreatic β-cell degeneration, and diabetes. Cold Spring Harb Perspect Med. 2012;2(9):a007666.

8. Marchetti P, Bugliani M, Lupi R, et al. The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. Diabetologia. 2007;50(12):2486-2494.

9. Cnop M, Toivonen S, Igoillo-Esteve M, Salpea P. Endoplasmic reticulum stress and eIF2α phosphorylation: the Achilles heel of pancreatic β-cells. Mol Metab. 2017;6(9):1024-1039.

10. Engin F, Yermalovich A, Nguyen T, et al. Restoration of the unfolded protein response in pancreatic β-cells protects mice against type 1 diabetes. Sci Transl Med. 2013;5(211):211ra156.

11. Tersey SA, Nishiki Y, Templin AT, et al. Islet β-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the nonobese diabetic mouse model. Diabetes. 2012;61(4):818-827.

12. Marfihour I, Lopez XM, Lefkaditis D, et al. Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes. Diabetologia. 2012;55(9):2417-2420.

13. Shrestha N, De Franco E, Arvan P, Cnop M. Pathological β-cell endoplasmic reticulum stress in type 2 diabetes: current evidence. Front Endocrinol (Lausanne). 2021;12:650158.

14. Marre ML, McGinty JW, Chow IT, et al. Modifying enzymes are elicited by ER stress, generating epitopes that are selectively recognized by CD4+ T cells in patients with type 1 diabetes. Diabetes. 2018;67(7):1356-1368.

15. Pandey VK, Mathur A, Kakkar P. Emerging role of unfolded protein response (UPR) mediated proapoptotic effects in diabetes. Life Sci. 2019;216:246-238.

16. Gardner BM, Pincus D, Gotthardt K, Gallagher CM, Walter P. Endoplasmic reticulum stress sensing in the unfolded protein response. Cold Spring Harb Perspect Biol. 2013;5(3):a013169.

17. Rao RV, Bredesen DE. Misfolded proteins, endoplasmic reticulum stress and neurodegeneration. Curr Opin Cell Biol. 2004;16(6):653-662.

18. Hassler JR, Scheuner DL, Wang S, et al. The IRE1α/XBP1s pathway is essential for the glucose response and protection of β cells. PLoS Biol. 2015;13(10):e1002277.

19. Tsuchiya Y, Saito M, Kadokura H, et al. IRE1-XBP1 pathway regulates oxidative proinsulin folding in pancreatic β-cells. J Cell Biol. 2018;217(4):1287-1301.

20. Usui M, Yamaguchi S, Tanji Y, et al. Atf6a-null mice are glucose intolerant due to pancreatic β-cell failure on a high-fat diet but partially resistant to diet-induced insulin resistance. Metabolism. 2012;61(8):1118-1128.

21. Zhang P, McGrath BC, Reinert J, et al. The GCN2 eIF2α kinase is required for adaptation to amino acid deprivation in mice. Mol Cell Biol. 2002;22(19):6681-6688.

22. Lee K, Tirasophon W, Shen X, et al. IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes Dev. 2002;16(4):452-466.

23. Park SM, Kang TI, So JS. Roles of XBP1s in transcriptional regulation of target genes. Biomedicines. 2021;9(7):791.

24. Lee AH, Heideman K, Horamisligil GS, Glumcher LH. Dual and opposing roles of the unfolded protein response regulated by IRE1alpha and XBP1 in proinsulin processing and insulin secretion. Proc Natl Acad Sci U S A. 2011;108(21):8885-8890.

25. Shen J, Pryvyes R. Dependence of site-2 pro tease cleavage of ATF6 on prior site-1 pro tease digestion is determined by the size of the luminal domain of ATF6. J Biol Chem. 2004;279(41):43046-43051.

26. Ye J, Rawson RB, Komuro R, et al. ER Stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol Cell. 2000;6(6):1355-1364.

27. Bommasamy H, Back SH, Fagone P, et al. ATF6α induces XBP1-independent expansion of the endoplasmic reticulum. J Cell Sci. 2009;122(10):1626-1636.

28. Baird TD, Wek RC. Eukaryotic initiation factor 2 phosphorylation and translational control in metabolism12. Adv Nutr. 2012;3(3):307-321.

29. Deng F, Wei J, Gupta S, McGrath BC, Cavender DR. Acute ablation of PERK results in ER dysfunctions followed by reduced insulin secretion and cell proliferation. BMC Cell Biol. 2009;10(1):61.

30. Harding HP, Zeng H, Zhang Y, et al. Diabetes mellitus and exocrine pancreatic dysfunction in Perk–/– mice reveals a role for translational control in secretory cell survival. Mol Cell. 2001;7(6):1153-1163.

31. Gao Y, Sartori DJ, Li C, et al. PERK is required in the adult pancreas and is essential for maintenance of glucose homeostasis. Mol Cell Biol. 2012;32(24):5129-5139.

32. Rozpondek W, Pytel D, Mucha B, Leszczyńska H, Diehl JA, Majsterek I. The role of the PERK/eIF2α/ATF4/CHOP signaling pathway in tumor progression during endoplasmic reticulum stress. Curr Mol Med. 2016;16(6):533-544.

33. Song B, Scheuner D, Ron D, Pennathur S, Kaufman RJ. Chop deletion reduces oxidative stress, improves beta cell function, and promotes cell survival in multiple mouse models of diabetes. J Clin Invest. 2008;118(10):3378-3389.

34. Yong J, Parekh VS, Reilly SM, et al. Chop/Ddit3 deletion in β cells alleviates ER stress and corrects hepatic steatosis in mice. Sci Transl Med. 2013;5(60):ea49796.

35. Sato T, Abiru N, Kobayashi M, et al. CHOP deletion does not impact the development of diabetes but suppresses the early production of insulin autoantibody in the NOD mouse. Apoptosis. 2011;16(4):438-448.

36. Chen CW, Guan BJ, Alzahrani MR, et al. Adaptation to chronic ER stress enforces pancreatic β-cell plasticity. Nat Commun. 2022;13(1):4621.

37. Lytton J, Westlin M, Burk SE, Shull GE, MacLennan DH. Functional comparisons between isoforms of the sarcoplasmic or endoplasmic reticulum family of calcium pumps. J Biol Chem. 1992;267(20):14483-14489.

38. Tong X, Kono T, Anderson-Baucum EK, et al. SERCA2 deficiency impairs pancreatic β-cell function in response to diet-induced obesity. Diabetes. 2016;65(10):3039-3052.

39. Fonseca SG, Ishigaki S, Oslowski CM, et al. Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells. J Clin Invest. 2010;120(3):744-755.

40. Urano F, Wolfram syndrome: diagnosis, management, and treatment. Curr Diab Rep. 2016;16(1):6.

41. Pakos-Zezulka K, Koryga I, Mnich K, Ljubicic M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016;17(10):1374-1395.
42. Costa-Mattioli M, Walter P. The integrated stress response: from mechanism to disease. *Science*. 2020;368(6489):eaat5314.

43. Wek RC, Jiang HY, Anthony TG, Coping with stress: eIF2 kinases and translational control. *Biochim Biophys Acta*. 2006;1743(4 Pt 1):7-11.

44. Donnelly N, Gorman AM, Gupta S, Samali A. The eIF2α kinases: their structures and functions. *Cell Mol Life Sci*. 2013;70(19):3493-3511.

45. de Aldana CRV, Wek RC, Segundo PS, Truesdell AG, Hinnebusch AG. Multiplex rRNA genes functionally suppress mutations in yeast eIF-2 alpha kinase GCN2: evidence for separate pathways coupling GCN4 expression to uncharged tRNA. *Mol Cell Biol*. 1994;14(12):7920-7932.

46. Dong J, Qiu H, Garcia-Barrio M, Anderson J, Hinnebusch AG. Uncharged tRNA activates GCN2 by displacing the protein kinase moiety from a bipartite tRNA-binding domain. *Mol Cell*. 2000;6(2):269-279.

47. Kanno A, Asahara S, Furubayashi A, et al. GCN2 regulates pancreatic β-cell mass by sensing intracellular amino acid levels. *JCI Insight*. 2020;5(9):e128820.

48. Lemaire PA, Anderson E, Lary J, Cole JL. Mechanism of PKR activation by dsRNA. *J Mol Biol*. 2008;381(2):351-360.

49. Clemens MJ, Elia A. The double-stranded RNA-dependent protein kinase PKR: structure and function. *J Interferon Cytokine Res*. 1997;17(9):503-524.

50. Vattem KM, Staschke KA, Wek RC. Mechanism of activation of the double-stranded-RNA-dependent protein kinase PKR: role of dimerization and cellular localization in the stimulation of PKR phosphorylation of eukaryotic initiation factor-2 (eIF2). *Environ Microbiol*. 2001;268(13):3674-3684.

51. Apalozza PS, Balcacean D, Zapardiel-Gonzalo J, et al. nPOD-Virus Group. Islet expression of type I interferon response sensors is associated with immune infiltration and viral infection in type 1 diabetes. *Sci Adv*. 2021;7(9):eabd6527.

52. Tang X, Uhl S, Zhang T, et al. SARS-CoV-2 infection induces beta cell transdifferentiation. *Cell Metab*. 2021;33(8):1577-1591.e7.

53. Udumula MP, Mangali S, Kralja J, et al. High fructose and streptozotocin induced diabetic impairments are mitigated by indirubin-3-hydrazone via downregulation of PKR pathway in Wistar rats. *Sci Rep*. 2021;11(1):12924.

54. Han AR, Yu C, Lu L, et al. Heme-regulated eIF2alpha kinase (HRI) is required for translational regulation and survival of erythroid precursors in iron deficiency. *EMBO J*. 2001;20(23):6909-6918.

55. Ill-Raga G, Tajes M, Busquets-Garcia A, et al. Physiological control of nitric oxide in neuronal BACE1 translation by heme-regulated eIF2alpha kinase HR1 induces synaptogenesis. *Antioxid Redox Signal*. 2015;22(15):1295-1307.

56. McEwen E, Kedersha N, Song B, et al. Heme-regulated inhibitor kinase-mediated phosphorylation of eukaryotic translation initiation factor 2 inhibits translation, induces stress granule formation, and mediates survival upon arsenite exposure. *J Biol Chem*. 2005;280(17):16925-16933.

57. Yerlikaya A, Kimball SR, Stanley BA. Phosphorylation of eIF2α in response to 26S proteasome inhibition is mediated by the haem-regulated inhibitor (HRI) kinase. *Biochem J*. 2008;412(3):579-588.

58. Palam LR, Baird TD, Wek RC. Phosphorylation of eIF2 facilitates ribosomal bypass of an inhibitory upstream ORF to enhance CHOP translation. *J Biol Chem*. 2011;286(13):10939-10949.

59. Wu Y, Zhang Z, Li Y, Li Y. The regulation of integrated stress response signaling pathway on viral infection and viral antagonism. *Front Microbiol*. 2022;12:814635.

60. de Jong OG, Verhaar MC, Chen Y, et al. Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes. *J Extrcell Vesicles*. 2012;1(1):18396.

61. Jimenez L, Yu H, McKenzie AJ, et al. Quantitative proteomic analysis of small and large extracellular vesicles (EVs) reveals enrichment of adhesion proteins in small EVs. *J Proteome Res*. 2019;18(3):947-959.

62. Statello L, Maugeri M, Garre E, et al. Identification of RNA-binding proteins in exosomes capable of interacting with different types of RNA: RBP-facilitated transport of RNAs into exosomes. *PLoS One*. 2018;13(4):e0195969.

63. Aguirre RS, Kulkarni A, Becker MW, et al. Extracellular vesicles in β cell biology: role of lipids in vesicle biogenesis, cargo, and intercellular signaling. *Mol Metab*. 2022;63:101545.

64. Wheeler JR, Matheny T, Jain S, Abrisch R, Parker R. Distinct stages in stress granule assembly and disassembly. *Elife*. 2016;5:e18413.

65. Piñeros AR, Kulkarni A, Gao H, et al. Proinflammatory signaling in islet β cells propagates invasion of pathogenic immune cells in autoimmune diabetes. *Cell Rep*. 2022;39(13):111011.

66. Martin S, Zeki R, Metz A, et al. Deficiency of G3BP1, the stress granules assembly factor, results in abnormal synaptic plasticity and calcium homeostasis in neurons. *J Neurochem*. 2013;125(2):175-184.

67. Anderson-Baucum E, Piñeros AR, Kulkarni A, et al. Deoxyhypusynpe synthase promotes a pro-inflammatory macrophage phenotype. *Cell Metab*. 2021;33(9):1883-1893.e7.

68. Kulkarni A, Anderson CM, Mirmira RG, Tersey SA. Role of polyamines and hypusine in β cells and diabetes pathogenesis. *Metabolites*. 2022;12(4):344.

69. Li CH, Ohn T, Ivanov P, Tisdale S, Anderson P. eIF5A promotes translation elongation, polysome disassembly and stress granule assembly. *PLoS One*. 2010;5(4):e9942.

70. Colvin SC, Maier B, Morris DL, Tersey SA, Mirmira RG. Deoxyhypusynpe synthase promotes differentiation and proliferation of β helper type 1 (Th1) cells in autoimmune diabetes. *J Biol Chem*. 2013;288(51):36226-36235.

71. Imam S, Prathibha R, Dar P, et al. eIF5A inhibition influences T cell dynamics in the pancreatic microenvironment of the humanized mouse model of type 1 diabetes. *Sci Rep*. 2019;9(1):1533.

72. Anderson A, Kulkarni A, Mirmira RG. 259-LB: inhibition of the polyamine-hypusine-circuit delimits islet β-cell stress in the context of T1D via suppression of Ire1α signaling. *Diabetes*. 2022;71(Suppl 1):259-LB.

73. Hiller H, Beachy DE, Lebowitz JJ, et al. Monogenic diabetes and integrated stress response genes display altered gene expression in type 1 diabetes. *Diabetes*. 2021;70(8):1885-1897.

74. Cao SS, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease. *Antioxid Redox Signal*. 2014;21(3):396-413.

75. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. *Physiol Rev*. 2014;94(3):909-950.

76. Pham-Huy LA, He H, Pham-Huy C. Free radicals, antioxidants in disease and health. *Int J Biomed Sci*. 2008;4(2):89-96.

77. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. *Nature*. 2000;408(6809):1375-1376.

78. Del Rio LA, López-Huertas E. ROS generation in peroxisomes and its role in cell signaling. *Plant Cell Physiol*. 2016;57(7):1364-1376.

79. Schrader M, Fahimi HD. Peroxides and oxidative stress. *Biochim Biophys Acta*. 2006;1763(12):1755-1766.

80. Phaniendra A, Jestadi DB, Periyasamy L. Free radicals: properties, sources, targets, and their implication in various diseases. *Indian J Clin Biochem*. 2015;30(1):11-26.

81. Holmström KM, Finkel T. Cellular mechanisms and physiological consequences of redox-dependent signaling. *Nat Rev Mol Cell Biol*. 2014;15(6):411-421.

82. Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: impact on human health. *Pharmacogn Rev*. 2010;4(8):118-126.

83. Maritim AC, Sanders RA, Watkins JB. Diabetes, oxidative stress, and antioxidants: a review. *J Biochem Mol Toxicol*. 2003;17(1):24-38.
84. Di Naso FC, Simões Dias A, Porawski M, Marroni NAP. Exogenous superoxide dismutase: action on liver oxidative stress in animals with streptozotocin-induced diabetes. *Exp Diabetes Res.* 2011;2011:754132.

85. Celic P, Gabai G. Oxidant/antioxidant balance in animal nutrition and effects on health. *Nutrients.* 2010;2(4):938-966.

86. Winczura A, Dzdzalik D, Tudek B. Damage of DNA and proteins by major lipid peroxidation products in genome stability. *Free Radic Res.* 2012;46(4):442-459.

87. Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. *J Biol Chem.* 1997;272(33):20313-20316.

88. Pizzino G, Irrera N, Cucinotta M, et al. Oxidative stress: harms and benefits for human health. *Oxid Med Cell Longev.* 2017;2017:8416763.

89. Krakauer T. mTORC1 activation, and metabolic derangement contribute to the susceptibility of diabetics to infections. *Med Hypotheses.* 2015;85(6):997-1001.

90. Son Y, Cheong YK, Kim NH, Chung HT, Kang DG, Paе HO. Mitogen-activated protein kinases and reactive oxygen species: how can ROS activate MAPK pathways? *J Signal Transduct.* 2011;2011:792639.

91. Chelombitko MA. Role of reactive oxygen species in inflammation: a minireview. *Moscow Univ Biol Sci Bull.* 2018;73(4):199-202.

92. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. *Antioxid Redox Signal.* 2014;20(7):1124-1126.

93. Nguyen T, Noi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. *J Biol Chem.* 2009;284(20):13291-13295.

94. Aleksunes LM, Reisman SA, Yeager RL, Goedken MJ, Klaassen CD. Nuclear factor erythroid 2-related factor 2 deletion impairs glucose tolerance and exacerbates hyperglycemia in type 1 diabetic mice. *J Pharmacol Exp Ther.* 2010;333(1):140-151.

95. Lou Y, Kong M, Li L, et al. Inhibition of the Keap1/Nrf2 signaling pathway significantly promotes the progression of type 1 diabetes mellitus. *Oxid Med Cell Longev.* 2021;2021:7866720.

96. Marra G, Crotoneo P, Pitocco D, et al. Early increase of oxidative stress and reduced antioxidative defenses in patients with uncomplicated type 1 diabetes: a case for gender difference. *Diabetes Care.* 2002;25(2):370-375.

97. Yagishita Y, Urano A, Chartoumpekis DV, Kessler TW, Yamamoto M. Nrf2 represses the onset of type 1 diabetes in non-obese diabetic mice. *J Endocrinol* 2019; 240(3):403-416. doi:10.1530/JOE-18-0355

98. Wall SB, Oh JY, Diers AR, Landar A. Oxidative modification of protein, prevents autoimmune and streptozotocin-induced diabetes. *Diabetologia.* 2011;2011:754132.

99. Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA. 8-Hydroxy-2'-deoxyguanosine, an abundant form of oxidative DNA damage, causes G-T and A-C substitutions. *J Biol Chem.* 1992;267(1):166-172.

100. Wyld L, Bellantuono I, Tchonkia T, et al. Senescence and cancer: a review of clinical implications of senescence and senotherapies. *Cancers (Basel).* 2020;12(8):2134.

101. Kwiecien S, Jasnos K, Magierowski M, et al. Lipid peroxidation, reactive oxygen species and antioxidative factors in the pathogenesis of gastric mucosal lesions and mechanism of protection against oxidative stress-induced gastric injury. *J Physiol Pharmacol.* 2014;65(5):613-622.

102. Landar A, Zmijewski JW, Dickinson DA, et al. Interaction of electrophilic lipid oxidation products with mitochondria in endothelial cells and formation of reactive oxygen species. *Am J Physiol Heart Circ Physiol.* 2006;290(5):H1777-H1787.

103. Ross D, Siegel D. The diverse functionality of NQO1 and its roles in health and disease: from molecular mechanisms to therapeutic opportunities. *Antioxid Redox Signal.* 2011;15(7):1957-1997.

104. Berberoglu Z, Sahiner UM, Sackesen C, Erzurum SC, Kalayci O. Oxidative stress and antioxidant defense. *World Allergy Organ J.* 2012;5(1):9-19.

105. Birben E, Sahiner UM, Sackesen C, Erzurum SC, Kalayci O. Oxidative stress and antioxidant defense. *World Allergy Organ J.* 2012;5(1):9-19.

106. Pizzi M, Faccio M, Ascierto PA, et al. Reactive oxygen species and antioxidative factors in the pathogenesis of allergic asthma. *Front Immunol.* 2012;3:148.

107. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. *Antioxid Redox Signal.* 2014;20(7):1124-1126.

108. Celic P, Gabai G. Oxidant-antioxidant balance in animal nutrition and health: the role of protein oxidation. *Front Vet Sci.* 2015;2:88.

109. Chelombitko MA. Role of reactive oxygen species in inflammation: a minireview. *Moscow Univ Biol Sci Bull.* 2018;73(4):199-202.

110. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. *Antioxid Redox Signal.* 2014;20(7):1124-1126.

111. Chelombitko MA. Role of reactive oxygen species in inflammation: a minireview. *Moscow Univ Biol Sci Bull.* 2018;73(4):199-202.

112. Chelombitko MA. Role of reactive oxygen species in inflammation: a minireview. *Moscow Univ Biol Sci Bull.* 2018;73(4):199-202.

113. Chelombitko MA. Role of reactive oxygen species in inflammation: a minireview. *Moscow Univ Biol Sci Bull.* 2018;73(4):199-202.
Kulkarni A, Nadler JL, Mirmira RG, Casimiro I. Regulation of tissue inflammation by 12-lipoxygenases. *Biochimie*. 2021;115(5):717.

Tersey SA, Maier B, Nishi Y, Maganti AV, Nadler JL, Mirmira RG. 12-Lipoxygenase promotes obesity-induced oxidative stress in pancreatic islets. *Mol Cell Biol*. 2014;34(19):3735-3745.

Stancill JS, Hansen PA, Mathison AJ, Schmidt EE, Corbett JA. Deletion of thioredoxin reductase disrupts redox homeostasis and impairs β-cell function. *Function (Oxf)*. 2022;3(4):eaac3034.

Kulkarni A, Pineros AR, Walsh MA, et al. Oxidative stress governs the innate immune pathogenesis of islet inflammation and autoimmunity diabetes. *JCI Insight*. 2021;6(14):147812.

Masson E, Koren S, Razik F, et al. High beta-cell mass prevents streptozotocin-induced diabetes in thioredoxin-interacting protein-deficient mice. *Am J Physiol Endocrinol Metab*. 2009;296(6):E1251-E1261.

Jing G, Westwell-Roper C, Chen J, Xu G, Verchere CB, Shalev A. Thioredoxin-interacting protein promotes islet amyloid polypeptide expression through miR-124a and FoxA2. *J Biol Chem*. 2014;289(17):11807-11815.

Haskins K, Bradley B, Powers K, et al. Oxidative stress in type 1 diabetes. *Am J Acad Sci*. 2003;100S(1):43-54.

Chou ST, Tseng ST. Oxidative stress markers in type 2 diabetes patients with diabetic nephropathy. *Clin Exp Nephrol*. 2017;21(2):283-292.

Francescato MP, Stel G, Geat M, Cauci S. Oxidative stress in patients with type 1 diabetes mellitus: is it affected by a single bout of prolonged exercise? *PloS One*. 2014;9(6):e99062.

Morandi A, Corradi M, Orsi S, et al. Oxidative stress in youth with type 1 diabetes: not only a matter of gender, age, and glycemic control. *Diabetes Res Clin Pract*. 2021;179:109007.

Liu CW, Bramer L, Webb-Robertson BJ, Waugh K, Rewers MJ, et al. Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents. *Diabetes Care*. 1998;21(10):1736-1742.

Göth L, Eaton JW. Hereditary catalase deficiencies and increased risk of diabetes. *Lancet*. 2000;356(9244):1820-1821.

He C, Klonovsky DJ. Regulation mechanisms and signaling pathways of autophagy. *Annu Rev Genet*. 2009;43(1):67-93.

Hansen M, Rubinsztein DC, Walker DW. Autophagy as a promoter of longevity: insights from model organisms. *Nat Rev Mol Cell Biol*. 2018;19(9):579-593.

Mizushima N. Autophagy: process and function. *Genes Dev*. 2007;21(22):2861-2873.

Cuervo AM. Chaperone-mediated autophagy: Dice’s “Wild” idea about lysosomal selectivity. *Nat Rev Mol Cell Biol*. 2011;12(8):535-541.

Li W, Li J, Bao J. Microautophagy: lesser-known self-eating. *Cell Mol Life Sci*. 2012;69(7):1125-1136.

Ramos-Rodriguez M, Pérez-González B, Pasquali L. The β-cell genomic landscape in T1D: implications for disease pathogenesis. *Curr Diab Rep*. 2021;21(1):1.

Jung HS, Chung KW, Won Kim J, et al. Loss of autophagy diminishes pancreatic beta cell mass and function with resultant hyperglycemia. *Cell Metab*. 2008;8(4):318-324.

Pearson GL, Gingerich MA, Walker EM, Biden TJ, Soleimanzadeh S. A selective look at autophagy in pancreatic β-cells. *Diabetes*. 2021;70(6):1229-1241.

Bartolome A, Guillen C, Benito M. Autophagy plays a protective role in endoplasmic reticulum stress-mediated pancreatic β cell death. *Autophagy*. 2012;8(12):1757-1768.

Muralidharan C, Linnemann AK. β-Cell autophagy in the pathogenesis of type 1 diabetes. *Am J Physiol Endocrinol Metab*. 2021;321(3):E410-E416.

148. Yamamoto S, Kuramoto K, Wang N, et al. Autophagy differentially regulates insulin production and insulin sensitivity. *Cell Rep*. 2018;23(11):3286-3299.

149. Muralidharan C, Conte AM, Marasco MR, et al. Pancreatic beta cell autophagy is impaired in type 1 diabetes. *Diabetologia*. 2021;64(4):865-877.

150. Abe H, Uchida T, Hara A, et al. Exendin-4 improves β-cell function in autophagy-deficient β-cells. *Endocrinology*. 2013;154(12):4512-4524.

151. Masini M, Bugliani M, Lupi R, et al. Autophagy in human type 2 diabetes pancreatic beta cells. *Diabetologia*. 2009;52(6):1083-1086.

152. Honda A, Komiya K, Hara A, et al. Normal pancreatic β-cell function in mice with RIP-Cre-mediated inactivation of p62/SQSTM1. *Endocr J*. 2018;65(1):83-89.

153. Hoshino A, Ariyoshi M, Okawa Y, et al. Inhibition of p53 preserves Parkin-mediated mitophagy and pancreatic β-cell function in diabetes. *Proc Natl Acad Sci U S A*. 2014;111(8):3116-3121.

154. Corsa CAS, Pearson GL, Renberg A, et al. The E3 ubiquitin ligase parkin is dispensable for metabolic homeostasis in murine pancreatic β cells and adipocytes. *J Biol Chem*. 2019;294(18):7296-7307.

155. Soleimanzadeh SA, Gupta A, Bakay M, et al. The diabetes susceptibility gene Clec16a regulates mitophagy. *Cell*. 2014;157(7):1577-1590.

156. Chen L, Liu C, Gao J, et al. Inhibition of Miro1 disturbs mitophagy and pancreatic β-cell function interfering insulin release via IRS-Akt-Foxo1 in diabetes. *OncoTarget*. 2017;8(53):90691-90705.

157. Binger KJ, Neukam M, Tarrakota SG, et al. Atypical deletion causes extensive vacuolation that consumes the insulin content of pancreatic β cells. *Proc Natl Acad Sci U S A*. 2019;116(40):19983-19988.

158. Floyed T, Brorsson C, Nielsen LB, et al. CTSH regulates β-cell function and disease progression in newly diagnosed type 1 diabetes patients. *Proc Natl Acad Sci U S A*. 2014;111(28):10305-10310.

159. Herranz N, Gil J. Mechanisms and functions of cellular senescence. *J Clin Invest*. 2018;128(4):1238-1246.

160. Muñoz-Espin D, Serrano M. Cellular senescence: from physiology to pathology. *Nat Rev Mol Cell Biol*. 2014;15(7):482-496.

161. Brawerman G, Thompson PJ. Beta cell therapies for preventing type 1 diabetes: from bench to bedside. *Biomolecules*. 2020;10(12):E1681.

162. Aguayo-Mazzucato C, Andle J, Lee TB, et al. Acceleration of β-cell aging determines diabetes and senolysis improves disease outcomes. *Cell Metab*. 2019;30(1):129-142.e4.

163. Thompson PJ, Shah A, Ntranos V, Van Gool F, Atkinson M, Bhushan A. Targeted elimination of senescent β-cells prevents type 1 diabetes. *Cell Metab*. 2019;29(5):1045-1060.e10.

164. Horwitz E, Krogvold L, Zhitomirsky S, et al. A β-cell function and disease robustness gene Clec16a regulates mitophagy. *Cell*. 2014;157(7):1577-1590.

165. Miyazaki S, Nakanishi K, Sugiyama T, et al. Accelerated β-cell death partially regulates insulin production and insulin sensitivity. *JCI Insight*. 2014;371-374.

166. Wang B, Wang L, Gasek NS, et al. An inducible p21-Cre mouse model to monitor and manipulate p21-highly-expressing senescent cells in vivo. *Nat Aging*. 2021;1(10):962-973.

167. Abbado C, Pluquet O. Unfolded protein response (UPR) controls major senescence hallmarks. *Trends Biochem Sci*. 2020;45(5):371-374.

168. Ammalia C, Drury WJ, Knerr L, et al. Targeted delivery of antisense oligonucleotides to pancreatic β-cells. *Sci Adv*. 2018;4(10):eaat3386.

169. Knerr L, Prakash TP, Lee R, et al. Glucagon like peptide 1 receptor agonists for targeted delivery of antisense oligonucleotides to pancreatic beta cells. *J Am Chem Soc*. 2021;143(9):3416-3429.

170. Moulton JD. Using morpholinos to control gene expression. *Curr Protoc Nucleic Acid Chem*. 2006;27(1):4301-43024.
Chen S, Shuh N, Veedu RN. Antisense oligonucleotides as potential therapeutics for type 2 diabetes. *Nucleic Acid Ther*. 2021;31(2):39-57.

Rehman KK, Trucco M, Wang Z, Xiao X, Robbins PD. AAV8-mediated gene transfer of interleukin-4 to endogenous β-cells prevents the onset of diabetes in NOD mice. *Mol Ther*. 2008;16(8):1409-1416.

Sahin GS, Lee H, Engin F. An accomplice more than a mere victim: the impact of β-cell ER stress on type 1 diabetes pathogenesis. *Mol Metab*. 2021;54:101365.

Fandey S, Dvorakova MC. Future perspective of diabetic animal models. *Endocr Metab Immune Disord Drug Targets*. 2020;20(1):25-38.

Ovalle F, Grimes T, Xu G, et al. Verapamil and beta cell function in adults with recent-onset type 1 diabetes. *Nat Med*. 2018;24(8):1108-1112.

Rubinsztejn DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. *Nat Rev Drug Discov*. 2012;11(9):709-730.

Towers CG, Thorburn A. Therapeutic targeting of autophagy. *EBioMedicine*. 2016;14:15-23.

Galluzzi L, Bravo-San Pedro JM, Levine B, Green DR, Kroemer G. Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. *Nat Rev Drug Discov*. 2017;16(7):487-511.

Brawerman G, Pipella J, Thompson PJ. DNA damage to β cells in culture recapitulates features of senescent β cells that accumulate in type 1 diabetes. *Mol Metab*. 2022;62:101524.

Bergmann TJ, Fregno I, Fumagalli F, et al. The role of islet-associated macrophages in type 2 diabetes. *Diabetes*. 2010;59(1):6-16.

Lee JH, Lee J. Endoplasmic reticulum (ER) stress and its role in pancreatic β-cell dysfunction and senescence. *Autophagy*. 2013(9)(10):1631-1632.

Lee JH, Lee J. Endoplasmic reticulum (ER) stress and impaired biogenesis of pancreatic β-cells that accumulate in type 1 diabetes. *Mol Metab*. 2022;62:101524.

Schlegel A, Gut P. Metabolic insights from zebrafish genetics, and diabetes. *Nat Rev Drug Discov*. 2012;11(9):5600-5612.

Sahin GS, Lee H, Engin F. An accomplice more than a mere victim: the impact of β-cell ER stress on type 1 diabetes pathogenesis. *Mol Metab*. 2021;54:101365.

Fandey S, Dvorakova MC. Future perspective of diabetic animal models. *Endocr Metab Immune Disord Drug Targets*. 2020;20(1):25-38.

Ovalle F, Grimes T, Xu G, et al. Verapamil and beta cell function in adults with recent-onset type 1 diabetes. *Nat Med*. 2018;24(8):1108-1112.

Rubinsztejn DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. *Nat Rev Drug Discov*. 2012;11(9):709-730.

Towers CG, Thorburn A. Therapeutic targeting of autophagy. *EBioMedicine*. 2016;14:15-23.

Galluzzi L, Bravo-San Pedro JM, Levine B, Green DR, Kroemer G. Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. *Nat Rev Drug Discov*. 2017;16(7):487-511.

Brawerman G, Pipella J, Thompson PJ. DNA damage to β cells in culture recapitulates features of senescent β cells that accumulate in type 1 diabetes. *Mol Metab*. 2022;62:101524.

Bergmann TJ, Fregno I, Fumagalli F, et al. The role of islet-associated macrophages in type 2 diabetes. *Diabetes*. 2010;59(1):6-16.

Lee JH, Lee J. Endoplasmic reticulum (ER) stress and its role in pancreatic β-cell dysfunction and senescence. *Autophagy*. 2013(9)(10):1631-1632.

Lee JH, Lee J. Endoplasmic reticulum (ER) stress and impaired biogenesis of pancreatic β-cells that accumulate in type 1 diabetes. *Mol Metab*. 2022;62:101524.

Schlegel A, Gut P. Metabolic insights from zebrafish genetics, and diabetes. *Nat Rev Drug Discov*. 2012;11(9):5600-5612.
214. Chen C, Ricks D, Gittes GK, et al. Autophagy protects pancreatic beta cell mass and function in the setting of a high-fat and high-glucose diet. Sci Rep. 2017;7(1):16348.

215. Chu KY, Mellet N, Thai LM, Meikle PJ, Biden TJ. Short-term inhibition of autophagy benefits pancreatic β-cells by augmenting ether lipids and peroxisomal function, and by countering depletion of n-3 polyunsaturated fatty acids after fat-feeding. Mol Metab. 2020;40:101023.

216. Ebato C, Uchida T, Arakawa M, et al. Autophagy is important in islet homeostasis and compensatory increase of beta cell mass in response to high-fat diet. Cell Metab. 2008;8(4):325-332.

217. Quan W, Hur KY, Lim Y, et al. Autophagy deficiency in beta cells leads to compromised unfolded protein response and progression from obesity to diabetes in mice. Diabetologia. 2012;55(2):392-403.

218. Blandino-Rosano M, Barbaresso R, Jimenez-Palomares M, et al. Loss of mTORC1 signalling impairs β-cell homeostasis and insulin processing. Nat Commun. 2017;8(1):16014.

219. Rodriguez A, Durán A, Selloum M, et al. Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. Cell Metab. 2006;3(3):211-222.